Chimeric natural killer receptor universal T-cell (ST Phi Therapeutics)

N/A

Report date: 2025/05/08 15:04:42

Base Information

Drug NameChimeric natural killer receptor universal T-cell (ST Phi Therapeutics)
Drug Alias NameUniversal CNK-UT Cell InjectionUniversal CNK-UT TherapyCNK-UT cells therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionNKG2D ligands modulatorsNatural cytotoxicity triggering receptor 2 Ligands modulators
TargetsNKG2D ligandsNatural cytotoxicity triggering receptor 2 Ligands
Therapy Area/IndicationsSolid tumoursGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesST Phi Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesST Phi Therapeutics Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsSolid tumoursGraft vs Host Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A